Akcea Therapeutics (AKCA) Tops Q3 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/28/2026
- Wall Street mostly rises as Fed holds key rate steady, deferring next likely hike to December
- SK Hynix shares surge after Q3 profit beats expectations
- Oil prices rise on Yemen fighting, Saudi refinery attack
- Alphabet stock rises as OpenAI plans to buy Google's TPUs
- Wendy's shares surge 16% on $1.4 billion takeover bid by Nelson Peltz’s Trian Fund
- Oracle sets $225 billion revenue target for FY30 at investor day
- S&P Global explores potential separation of Capital IQ business
- SpaceX stock drops amid spaceport lawsuit, debt concerns
- Rivian shares slip ahead of Thursday earnings release
- Moderna stock rises on latest cancer vaccine data publication
Akcea Therapeutics, Inc. (AKCA) PT Raised to $47 at BMO Capital
November 6, 2018 3:52 AM ESTBMO Capital analyst Do Kim raised the price target on Akcea Therapeutics, Inc. (NASDAQ: AKCA) to $47.00 (from $42.00) while maintaining a Outperform rating.
... More


